Holen Sie sich die Stockscreener-App
277.55
1.11%
-3.215
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Laboratories International (CRL) Could Be 8% Undervalued After Endosafe Automation Ramp - simplywall.st
One investor controls millions of Charles River (NYSE: CRL) shares - Stock Titan
Charles River Launches Automated Endosafe Manufacturing Suite - Contract Pharma
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite - Investing News Network
Charles River Labs stock holds steady as investors look to recent earnings - AD HOC NEWS
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Charles River Labs stock trades near yearly high as analysts flag valuation risks - AD HOC NEWS
Charles River Laboratories stock gains as valuation stretches above fair value estimates - AD HOC NEWS
How Investors Are Reacting To Charles River (CRL) Deepening Its Role In Complex Vaccine Development - simplywall.st
Charles River Laboratories International Inc (CRL) Shares Surge 3.3% -- What GF Score of 70 Tells Investors - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
LRT Capital Management, LLC's Charles River Laboratories International Inc(CRL) Holding History - GuruFocus
Is This the Right Time to Add CRL Stock to Your Portfolio? - Eastern Progress
Charles River Labs stock holds near recent highs as earnings beat and analyst optimism support the r - AD HOC NEWS
Is Charles River Laboratories International (CRL) Cheap After Its Medigen Vaccine Partnership? - simplywall.st
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River Laboratories (CRL) Stock Analysis: Navigating Growth Challenges with Strategic Collaborations - DirectorsTalk Interviews
Charles River Laboratories (CRL) Earnings History & Trends - 24/7 Wall St.
Resilient Charles River Labs stock trades close to its 52-week high as analysts see limited upside - AD HOC NEWS
Charles River (NYSE: CRL) director exercises options, sells stock at $300 - Stock Titan
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock? - inkl
Charles River (NYSE: CRL) director plans new sale after $24.8M stock sales - Stock Titan
Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today - Benzinga
Charles River and Medigen partner to speed up next-generation Enterovirus vaccine - Indian Pharma Post
Is Charles River (CRL) Quietly Redefining Its Edge Through Complex Biologics and Vaccine Testing? - simplywall.st
Charles River Labs stock holds close to new 52-week high as Q2 2026 beat and guidance hike support r - AD HOC NEWS
What Does Charles River Laboratories International (CRL) Gain From This Vaccine Collaboration? - simplywall.st
Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development? - Yahoo Finance
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running? - TradingView
Charles River Labs stock holds near fresh 52-week high after strong Q2 earnings - AD HOC NEWS
Are Options Traders Betting on a Big Move in Charles River Stock? - TradingView
Charles River Gains 88.6% in a Year: What's Driving the Rally? - Yahoo Finance
Madison Asset Management LLC Invests $3.81 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs CEO Birgit Girshick Gifts 528 Shares, Retains Significant Ownership - Kalkine Media
Charles River Laboratories Director Nancy C. Andrews Reports Form 4 Filing on Stock Option Exercise and Sale - Kalkine Media
Charles River Labs CEVP Parisotto sells $599,710 in shares By Investing.com - Investing.com Australia
Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares - MarketBeat
Charles River (NYSE: CRL) CEO makes 528-share gift of common stock - Stock Titan
Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat
Charles River Labs CEVP Parisotto sells $599,710 in shares - Investing.com
Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing - marketscreener.com
Charles River (NYSE: CRL) insider sells 2,039 shares in 10b5-1 plan - Stock Titan
Charles River (NYSE: CRL) director exercises options, sells 573 shares - Stock Titan
Charles River Labs stock hits fresh 52-week high as Medigen vaccine deal boosts sentiment - Ad-hoc-news.de
Charles River Laboratories stock hits 52-week high at $294.68 By Investing.com - Investing.com Nigeria
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing - BioSpace
Charles River Laboratories International, Inc. and Medigen Vaccine Biologics Corp. Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing - marketscreener.com
MEX:CRL EV-to-OCF: 27.30 — 36% Above Median - GuruFocus
Is Charles River Laboratories International Inc (CRL) Overvalued - GuruFocus
Charles River (NYSE: CRL) officer to sell 2,039 shares after option exercise - Stock Titan
Charles (CRL) Snapshot: Moves 4.77% Up to $292.52 in the Latest Session; Levels: the $277.89 to $307.15 Range Remains in FocusMotive Wave - Vinanet
Charles (CRL) Results Versus Estimates: Profit Per Share Surpasses Its Benchmark at the Close; Trading Move - Vinanet
Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued? - simplywall.st
Charles River Labs stock reaches new 12-month high as 2026 guidance lifts expectations - Ad-hoc-news.de
Charles River (NYSE: CRL) investor to sell 573 shares via UBS - Stock Titan
2.22%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):